Progyny Reports Strong Q1 2026 Earnings with 61% Net Income Growth and Completes $200M Share Buyback
Summary
Progyny reported strong Q1 2026 results, including a 61% increase in net income and a 70.6% rise in diluted EPS, alongside the completion of its $200 million share repurchase program.
Key Events
-
Strong Q1 2026 Financial Performance
Progyny reported net income of $24.2 million, a 61% increase from Q1 2025, and diluted EPS of $0.29, up 70.6%. Gross profit grew 10% to $83.1 million, with gross margin expanding by 190 basis points to 25.3%.
-
Completion of $200M Share Repurchase Program
The company completed its previously authorized $200 million share repurchase program, buying back 5,511,824 shares for $116.6 million in Q1 2026 at an average price of $21.13 per share.
-
Client and Member Base Expansion
Progyny expanded its client base to 595 (from 555 at year-end 2025) and its member base to 7.179 million (from 6.689 million), despite a modest 1% revenue increase attributed to the non-renewal of a large client in 2025.
-
CEO Terminates 10b5-1 Selling Plan
CEO Peter Anevski terminated a Rule 10b5-1 trading plan on January 26, 2026, which had provided for the sale of up to 1,244,220 shares.
Analysis
Progyny, Inc. filed its Q1 2026 earnings report, detailing robust financial performance with significant net income and EPS growth. The company successfully completed its $200 million share repurchase program, executing $116.6 million of repurchases in the first quarter alone. While revenue growth was modest at 1%, this was attributed to the previously disclosed non-renewal of a large client in 2025. The company demonstrated continued expansion in its client and member base. Additionally, the CEO's termination of a 10b5-1 selling plan removes a potential overhang, signaling a neutral to slightly positive sentiment regarding future insider selling.
At the time of this filing, PGNY was trading at $21.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.10 to $28.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.